Sean P. Nolan is a businessperson who has been at the head of 6 different companies. Mr. Nolan occupies the position of Executive Chairman for Istari Oncology, Inc., Chairman of Encoded Therapeutics, Inc., Chairman of Taysha Gene Therapies, Inc. and Chairman & President at Nolan Capital LLC.
He is also on the board of Ventas, Inc., Affinia Therapeutics, Inc. and Social Capital Suvretta Holdings Corp. II.
He previously was Chief Commercial Officer for Reata Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Novartis Gene Therapies, Inc., President & Chief Commercial Officer at Lundbeck, Inc., Chief Business Officer & Executive Vice President at InterMune, Inc. and Vice President-Marketing & Sales Operations at OVATION Pharmaceuticals, Inc.
Mr. Nolan received an undergraduate degree from John Carroll University.
What is Sean P. Nolan's net worth?
The estimated net worth of Sean P. Nolan is at least $12.83 million as of January 26th, 2026. Mr. Nolan owns 2,908,257 shares of Taysha Gene Therapies stock worth more than $12,825,413 as of February 6th. This net worth estimate does not reflect any other assets that Mr. Nolan may own. Additionally, Mr. Nolan receives a salary of $925,330.00 as Director at Taysha Gene Therapies. Learn More about Sean P. Nolan's net worth.
How old is Sean P. Nolan?
What is Sean P. Nolan's salary?
How do I contact Sean P. Nolan?
Has Sean P. Nolan been buying or selling shares of Taysha Gene Therapies?
During the last ninety days, Sean P. Nolan has sold $840,196.07 in Taysha Gene Therapies stock. Most recently, Sean P. Nolan sold 41,312 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a transaction totalling $190,448.32. Following the completion of the sale, the chief executive officer now directly owns 2,908,257 shares of the company's stock, valued at $13,407,064.77. Learn More on Sean P. Nolan's trading history.
Who are Taysha Gene Therapies' active insiders?
Are insiders buying or selling shares of Taysha Gene Therapies?
In the last twelve months, Taysha Gene Therapies insiders bought shares 1 times. They purchased a total of 750,000 shares worth more than $2,062,500.00. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 1,167,140 shares worth more than $5,156,612.66. The most recent insider tranaction occured on January, 26th when insider Sukumar Nagendran sold 26,918 shares worth more than $124,091.98. Insiders at Taysha Gene Therapies own 3.8% of the company.
Learn More about insider trades at Taysha Gene Therapies. Information on this page was last updated on 1/26/2026.
